FDA
-
-
-
-
-
-
-
Allena Pharmaceuticals Provides Clinical and Corporate Update
-
-
-
-
-
-
-
Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346
-
-
-
-
-
-
-
Allena Pharmaceuticals (ALNA) Provides Update on Clinical Development Programs
-
-
-
-
-
-
-
Allena Pharmaceuticals (ALNA) Names Mark J. Fitzpatrick to Board
-
-
-
-
-
-
-
Allena Pharmaceuticals (ALNA) Announces $10 Million Bought Deal Offering of Common Stock
-
-
-
-
-
-
-
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
-
-
-
-
-
-
-
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million
-
322,134 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

